Next Article in Journal
The Effects of In-Plane Spatial Resolution on CT-Based Radiomic Features’ Stability with and without ComBat Harmonization
Next Article in Special Issue
Minimal Disease Monitoring in Pediatric Non-Hodgkin’s Lymphoma: Current Clinical Application and Future Challenges
Previous Article in Journal
Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation
Previous Article in Special Issue
Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1–RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1–RUNX1T1
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 13
Issue 8
10.3390/cancers13081847
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions

Cancers 2021, 13(8), 1847; https://doi.org/10.3390/cancers13081847
by Gloria Paz Contreras Yametti 1,2, Talia H. Ostrow 2, Sylwia Jasinski 1,2, Elizabeth A. Raetz 1,2, William L. Carroll 1,2,* and Nikki A. Evensen 2
Reviewer 1:
Nils Von Neuhoff
Reviewer 2:
Anna Pasetto
Reviewer 3: Anonymous
Cancers 2021, 13(8), 1847; https://doi.org/10.3390/cancers13081847
Submission received: 2 March 2021 / Revised: 31 March 2021 / Accepted: 11 April 2021 / Published: 13 April 2021
(This article belongs to the Special Issue Minimal Residual Disease of Cancers)

Round 1

Reviewer 1 Report

The authors Yametti et al . have written an important summary on the importance of diagnosing MRD in ALL. The review article should be published with slight improvements or additions.

  1. The different methods for calculating MRD (ct and others) should be evaluated in a separate paragraph regarding strengths and weaknesses (absolute versus relative quantification).
  2. The authors should mention the issue of standardisation regarding the performance of interlaboratory comparisons.
  3. Figure 1 needs to be revised. The areas of flow MRD and molecular genetic MRD should be shown separately. The legend is too long and needs to be shortened.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

The review is clearly organised and written; it provides good information on the topic with satisfying level of details and appropriate references. The only comment is that the text under figure 1 is very extensive and detailed, perhaps part of that text should go in the main body of the review instead.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 3 Report

In the review entitled "Minimal residual disease in acute lymphoblastic leukemia: Current practice and future directions", the authors described the biological basis for utilizing MRD in risk assessment, considering also technical approaches and related limitations.

Major revisions:

In my opinion paragraphs 3-4-5-6 should be sub-paragraphs of nr.2, "Mehods Of Minimal Residual Disease Detection", and the amount of technical details should be reduced, supposing that the reader knows the basis of the presented methodologies.

Minor revisions:

- In the paragraph nr.3, "Multiparametric Flow Cytometry For Surface Proteins" line 75-85, flow cytometric analysis has been described with too much details.

- In the paragraph nr.4, "Polymerase Chain Reaction (PCR) Amplification of Antigen Receptor Rearrangements", in my opinion lines 124-129 have to be removed.

- The description of the legend of Figure 1 is redundant if compared to the main text. Insert the detailed description in the text or in the figure legend.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop